Corporate News – Market Performance Update
At 01:55 AM Central European Time on Friday, 23 October 2026, Bio‑techne (ticker: TECH) recorded a modest rise of 0.08 % during the preceding 24‑hour trading window. The share price closed at USD 72.62 on the principal exchanges, reflecting a cumulative increase of 0.12 % since the close of the previous month.
Market Metrics
- Shares outstanding: 156.8 million
- Market capitalization: USD 11.4 billion
- Volume: USD 254.1 million worth of shares exchanged over the past day
- 200‑day simple moving average: USD 62.92
- 52‑week high: USD 72.69 (22 September 2026)
- 52‑week low: USD 43.20 (18 May 2026)
The stock’s trajectory indicates a gradual ascent, yet it remains closely aligned with its long‑term trend, as evidenced by the modest deviation from the 200‑day average.
Comparative Peer Activity
The performance of several peer companies over the same 24‑hour period offers context for Bio‑techne’s movement:
| Company | Ticker | % Change (24 h) | Current Price (USD) | Market Capitalisation (USD) | P/E Ratio |
|---|---|---|---|---|---|
| Somnigroup | SGI | –1.67 % | 65.99 | 13.5 bn | 25.44 |
| Manhattan | MANH | +1.28 % | 242.17 | 13.6 bn | 66.47 |
| Ionq | IONQ | +3.26 % | 31.16 | 13.4 bn | – |
| Textron | TXT | +0.17 % | 78.04 | 13.3 bn | 14.42 |
| Bridgebio Pharma | BBIO | +0.28 % | 68.12 | 13.4 bn | – |
While Ionq displayed the most pronounced gain, Somnigroup’s decline contrasts with the relatively modest upward swing of Bio‑techne. Manhattan’s significant rise, however, highlights the volatility within the biotech‑focused sector.
Company Overview
Bio‑techne Corp is headquartered in Minneapolis, United States, and specializes in the development, manufacturing, and distribution of biotechnology products and clinical diagnostic controls. The company’s product portfolio includes proteins, cytokines, growth factors, immunoassays, and small molecules, positioning it at the intersection of research and clinical diagnostics. Bio‑techne was listed on the Nasdaq exchange following its initial public offering on 9 February 1989. For further details, visit the company’s website at www.bio‑techne.com .
